{"entity":{"id":"idea-prev-li-fraumeni-mri-plus-cfdna","kind":"idea","name":"Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome","aka":[],"tldr":"People with an inherited TP53 mutation face a near-certain lifetime cancer risk. Yearly whole-body MRI catches cancers early; adding blood DNA tests may catch them earlier still.","summary":"People with an inherited TP53 mutation face a near-certain lifetime cancer risk, so this idea builds a global Li-Fraumeni registry with standardised whole-body MRI surveillance plus prospective cell-free DNA and fragmentomics testing, to learn whether blood adds lead time over imaging. The Toronto Protocol of whole-body MRI, brain MRI and ultrasound already improved outcomes, the very high prior probability makes positive predictive value acceptable, and the multiplicity of tumour types favours a tumour-agnostic blood test. The test follows a 1,000-carrier prospective cohort for five years. At early-clinical maturity it addresses the bottlenecks Inherited risk is mostly unidentified and The hardest cancers are found late.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)","url":"https://doi.org/10.1200/JCO.2017.73.6314"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["prevention","imaging"],"technologies":["whole-body-mri","liquid-biopsy"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-hereditary-risk","b-early-detection"],"keyPapers":["paper-vogelstein-surfing-p53-network-nature-2000","paper-childers-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Adding cell-free DNA surveillance to imaging detects at least 30% of incident cancers before imaging, with lead time of six months or more.","rationale":"Very high prior probability makes positive predictive value acceptable, and the multiplicity of tumour types favours a tumour-agnostic blood test.","test":"Follow a 1,000-carrier prospective cohort over five years.","maturity":"early-clinical","actor":"research","cost":"medium","horizonYears":5},"route":"/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/"}],"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"bottleneck":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"paper":[{"id":"paper-childers-j-clin-oncol","kind":"paper","name":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","route":"/key-papers/paper-childers-j-clin-oncol/"},{"id":"paper-vogelstein-surfing-p53-network-nature-2000","kind":"paper","name":"Vogelstein, Lane and Levine 2000: surfing the p53 network","route":"/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/"}]}}